Cooperativity between endogenous glutamylcysteinylglycine-based oligopeptides and drugs determines the function of the multidrug transporter ABCC1
Year: 2025
Type: article
Abstract: The multidrug transporter ABCC1 confers resistance against many anticancer drugs, often together with endogenous glutamylcysteinylglycine. Neither highly potent inhibition of ABCC1-mediated drug transport, nor enhancement of ABCC1-mediated glutamylcysteinylglycine efflux and stress-related cell death, have worked out clinically as strategies to overcome multidrug resistance. This study sought to analyze the relationship between (i) the ABCC1 ATPase, which provides the energy for the transport process; (ii) ABCC1 co-substrates, such as glutamylcysteinylglycine derivatives; and (iii) ABCC1-targeting drugs. Glutamylcysteinylglycine disulfide showed strongest ABCC1 ATPase activation, which was further enhanced in combination with the ABCC1 ATPase activator indomethacin. Indomethacin and ABCC1 inhibitors exhibited reduced half-maximal activation and inhibition effect values of the ABCC1 ATPase in combination with glutamylcysteinylglycine disulfide. Kinetic and functional analyses provided evidence of a non-essential activation / allosteric competitive stimulation exerted by ABCC1 activators and inhibitors. Increase of both ABCC1 ATPase and ABCC1 transport activities triggered by targeting distinct ABCC1 binding sites through mutual affinity increase by glutamylcysteinylglycine derivative-drug combinations appears as a third, novel way to overcome ABCC1-mediated multidrug resistance.
Source: Biochemical Pharmacology
Authors: Katja Stefan, Muhammad Rafehi, Hauke Busch, Vigneshwaran Namasivayam, Sven Marcel Stefan
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,590
Funder: Deutsche Forschungsgemeinschaft
Awards: Rückkehrstipendium, Etablierung neuer Detektionsmethoden zur Entdeckung und Entwicklung neuer ABCA1 und ABCA7 Modulatoren als Alzheimer Therapeutika und Diagnostika, Design, Synthese und biologische Bewertung von ABC TransporterAgonisten zur Entwicklung neuer Alzheimer Therapeutika, EXC 2167: Präzisionsmedizin für Chronische Entzündungserkrankungen (PMI), Exploration von PanABCTransporterModulatoren durch innovative In Silico und In Vitro Methoden zur Generierung potentieller Zielstrukturen, Diagnostika und Therapeutika
OpenAlex ID: W4415081820
